Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian(Bloomberg (United States)), Mario Sznol(Yale University), Julie R. Brahmer(Johns Hopkins University), Robert A. Anders(Johns Hopkins University), Philip D. Leming(Oncology Hematology Care), Charles G. Drake(Columbia University Irving Medical Center), Lieping Chen(Yale Cancer Center), Janis M. Taube(Bloomberg (United States)), Alan J. Korman(Bristol-Myers Squibb (Germany)), Scott Antonia(Parker Institute for Cancer Immunotherapy), Jon M. Wigginton(Bristol-Myers Squibb (United States)), Michael B. Atkins(Georgetown University), D. G. McDonald(Bristol-Myers Squibb (United States)), Drew M. Pardoll(Bloomberg (United States)), Scott Gettinger(Yale Cancer Center), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Tracee L. McMiller(Johns Hopkins University), Georgia Kollia(Bristol-Myers Squibb (United States)), F. Stephen Hodi(Harvard University), Richard D. Carvajal(Northwell Health), William H. Sharfman(Johns Hopkins University), John D. Powderly(Carolina BioOncology Institute), Shruti Agrawal(Bristol-Myers Squibb (United States)), Leora Horn(Heidelberg University), Haiying Xu(Johns Hopkins University), Ashok Gupta, Maria Jure–Kunkel(Bristol-Myers Squibb (United States)), David F. McDermott(Beth Israel Deaconess Medical Center), David C. Smith(University of Michigan), David R. Spigel(Sarah Cannon)
Cited by 12,636
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5k